Teresa Montagut
Head of Clinical Development & Medical Affairs Mesoblast Ltd.
Seminars
Wednesday 2nd December 2026
Advancing Mesenchymal Stromal Cell Therapies for High Unmet Need Autoimmune Indications
11:30 am
- Demonstrating clinical value in steroid and JAK inhibitor refractory patients to position MSCs as a late-line option
- Showcasing validated potency assays to link cell quality with improved clinical outcomes
- Exploring allogeneic off-the-shelf MSC approaches to deliver broad immunosuppression with strong safety profiles
